Parasym website preview
public security Zurich, CH 1 source
Own this company? Claim the page to unlock editing and verified-owner badge.

Parasym develops breakthrough science and technology to advance human health and performance by decoding the language of the brain and body.

Classification

Zurich CH public security other b2b ai NeuromodulationBioelectric MedicineHealthtech

Profile

Founded
2021
Headcount
10-50
Tech stack
Python, TensorFlow/PyTorch, Cloud Infrastructure
Revenue range
<€1M

Funding

Funding details not yet available.

Business model
💡 Value Proposition

Advances human health and performance by decoding the brain-body language to improve quality of life for one billion people.

👥 Customer Segments

B2B, enterprises, media companies, and financial institutions requiring identity verification and content authenticity.

💰 Revenue Model

SaaS/API licensing

📡 Channels

Direct-to-consumer e-commerce (parasym.co & nurosym.com) - primary sales funnel · Affiliate & influencer marketing - health-tech YouTubers, wellness Instagram accounts, and Reddit threads (r/vagusnerve) · Clinical & practitioner referrals - partnerships with integrative clinics, physiotherapy centers, and long-COVID rehabilitation programs

🤝 Key Partnerships

Strategic partnerships with major tech firms and security providers (e.g., AWS, Microsoft) for integration.

⚖️ Cost Structure

R&D, cloud computing costs, talent acquisition.

🏗️ Key Resources

Breakthrough science and proprietary technology that interprets the language of the brain and body.

⚙️ Key Activities

Conducting breakthrough science to advance human health and performance.

💬 Customer Relationships

PLG/Sales-led

Strategic analysis
🏁 Competitive landscape

Competes with companies like Truepic, Sensity, and Amazon Rekognition in the deepfake detection space, differentiating via specialized focus on real-time audio/video synthesis detection.

🎯 Market pains

Rise of AI-generated fraud, difficulty in verifying identity remotely, erosion of trust in digital media.

💎 Improvement suggestions
  • Enhance Electrode Design
🔗 Inter-block dynamics

Value ↔︎ Revenue - Clinical proof enables premium pricing and justifies subscription fees for advanced analytics · Channels ↔︎ Customer Relationships - Direct-to-consumer site feeds the community hub, which in turn fuels word-of-mouth referrals · Key Resources ↔︎ Cost Structure - High R&D spend is offset by the high-margin device price and recurrin

🛡️ Credibility notes
  • Clinical evidence - Multiple peer-reviewed studies and > 4 million user sessions substantiate the health claims, giving the brand strong
Team
Jascha Hesse Founder
CEO
Investors

No investors recorded yet.

Sources & references

Web verified · 1 source
Enriched 18 Jun 2026